IMIM
International Master in Innovative Medicine

Duration
2 years

Course description
The Erasmus Mundus Joint Master Degree International Master in Innovative Medicine (IMIM) is a two-year international master of excellence focusing on the education of translational researchers and professionals. The IMIM mission is to educate a future generation of excellent translational scientists and professionals who have the skills and competences to work effectively in different multi-/interdisciplinary and internationally competitive academic and non-academic environments. IMIM is organised jointly by the University of Groningen (the Netherlands, Coordinator), Heidelberg University (Germany), and Uppsala University (Sweden) in Europe. Additionally, partnering us are four Higher Education Institutions (HEI) in Latin America: Universidade de São Paulo (Brazil), Pontificia Universidad Católica de Chile (Chile), Universidad de Antioquia (Colombia), and Universidad Nacional Autónoma de México (Mexico). All partners have a particular strength in biomedical sciences and are listed among the top of regional and international rankings.

IMIM builds on pre-existing partnerships that are the outcome of each university’s comprehensive internationalisation strategy to establish a network of excellence. The EU degree-awarding HEIs offer complementary expertise reflected in the three selective individual master’s programmes on which IMIM is built: the 2-year MSc Medical and Pharmaceutical Drug Innovation at Groningen; the 1-year MSc Translational Medical Research at Heidelberg, and the 2-year MMRs Molecular Medicine and Medical Research at Uppsala. Together, the Consortium offers access to excelling individuals from different disciplinary backgrounds, ranging from medical graduates to basic scientists, and everything in between. Moreover, IMIM integrates different joint elements in the educational programme, in particular the educational concept of a ‘Learning Line’ defined as “from Bench to Bedside and Back” (BBB). BBB forms the heart of IMIM, providing a platform for students to discover, apply and integrate knowledge and understanding from different disciplinary domains to address complex translational problems. The BBB joint curriculum is a total of 20 ECTS of assignments, as well as and a Spring and a Summer School. Students develop BBB background knowledge in the first semester, design a research proposal (2nd), write a business plan (3rd), and create a ‘BBB product’ – a research grant or a start-up company – in the final semester. Finally, IMIM strongly values the integration of the curriculum with the non-academic sector, in particular industry. Private sector partners are involved in IMIM through the BBB learning line, the Industrial Perspectives on Innovative Medicine Summer School, student research supervision, as well as the programme evaluation through their participation in the Advisory Board. The latter is extremely important in order to ensure that the IMIM learning outcomes remain relevant to the competences required by the labour market.

Web site
www.innovativemedicine.eu

Partners
RIJKSUNIVERSITEIT GRONINGEN, Netherlands (coordinating institution)
UNIVERSIDADE DE SAO PAULO, Brazil
PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE, Chile
UNIVERSIDAD DE ANTIOQUIA, Colombia
UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO, Mexico
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG, Germany
UPPSALA UNIVERSITET, Sweden

Contact
Mr. Jan Maarten van Dijl
Hanzeplein 1
NL-9713 GZ Groningen
imim@rug.nl